On March 17, 2026, R1 Therapeutics, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc., with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. Wilson Sonsini Goodrich & Rosati advised R1 on the financing.
Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year.
The Wilson Sonsini team that advised R1 on the transaction includes:
Corporate
Dan Koeppen
Phil McGill
Tim Conroy
Regulatory
Joshua Gruenspecht
For more information, please see R1’s news release. Additional coverage can be found on Fierce Biotech and Reuters.
